BiotechTube

VBR + AB-729 + SOC NrtI

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Hepatitis B

Conditions

Chronic Hepatitis B

Trial Timeline

May 7, 2021 → Mar 30, 2023

NCT ID
NCT04820686

About VBR + AB-729 + SOC NrtI

VBR + AB-729 + SOC NrtI is a phase 2 stage product being developed by Arbutus Biopharma for Chronic Hepatitis B. The current trial status is terminated. This product is registered under clinical trial identifier NCT04820686. Target conditions include Chronic Hepatitis B.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Hepatitis B were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04820686Phase 2Terminated

Competing Products

20 competing products in Chronic Hepatitis B

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25